Anti-Mouse Thy1.1 (CD90.1) [Clone 19E12] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse Thy1.1 (CD90.1) [Clone 19E12] — Purified in vivo GOLD™ Functional Grade
Product No.: C3101
Clone 19E12 Target Thy1.1 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Thy1.1, CD90.1 Isotype Mouse IgG2a k Applications FC |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Mouse Thy1.1 transfected cells. Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity 19E12 activity is directed against mouse Thy1.1 (CD90.1). Background Thy1 is a highly conserved, GPI-linked member of the immunoglobulin superfamily that is
important in the immune and nervous systems1 and involved in T cell activation and cell-cell
interactions2. The effects of Thy1 are context dependent1. Thy1 is heavily N-glycosylated with a
carbohydrate content of up to 40% of its molecular mass, and its moiety composition varies
between tissues as well as between cells of the same lineage in different stages of differentiation.
Additionally, Thy1 is found in both membrane-bound and soluble forms, and, in mouse, Thy1 is
encoded by two alleles, Thy1.1 and Thy1.2, which are distinguished by a single amino acid at
position 891. Thy1 deficiency does not compromise immunity2, but its presence or absence
modulates the phenotypes of certain cancers, fibrotic diseases, and neuronal injury1. Thy1.1 is an
alloantigen of the AKR/J and PL mouse strains2. 19E12 was generated by immunizing 129 strain mice with allogeneic AKR SL3 leukemia cells and fusing the resulting lymphocytes with BALB/c MOPC21 NSI/1 myeloma cells3. 19E12 showed specificity for Thy1.1 antigen in cytotoxic assays. Additionally, 19E12 was found to have antitumor activity in (B6 x AKR)F1 hybrid mice, AKR parental mice3 and AKR/J mice4 inoculated with AKR SL2 cells. Antitumor activity was enhanced when administered in combination with rat monoclonal antibody R17 2085. 19E12 antibody has been used to create a bispecific hybrid antibody that can focus T cell activity against Thy1.1-expressing tumor cells for lysis in vitro6. A biotinylated form has also been used as a tumor pretargeting agent to increase the local concentration and persistence of human tumor necrosis factor alpha on a mouse tumor7. 19E12 can also be used to deplete Thy1.1-expressing cells in mice8,9,10,11,12, both in naturally occurring Thy1.1+ T cells and in cells trangenically expressing Thy1.1 due to experimental design. Thy1 is widely used as a marker for thymus T cells13, thymus-derived lymphocytes, and lipid rafts in murine T cells2. Antigen Distribution Thy1.1 is present on the cell surface of mouse thymocytes, T-lymphocytes,
peripheral T cells, neurons, bone marrow stem cells, retinal ganglion cells, myoblasts, subsets of
fibroblasts, vascular pericytes, epidermal cells, activated endothelial cells, keratinocytes,
mesangial cells, and hematopoietic and mesenchymal stem cells. Ligand/Receptor Interacts with CD45 NCBI Gene Bank ID UniProt.org Research Area Cell Biology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 19E12 is most commonly used in vivo in mice to deplete cells expressing the Thy1.1 (CD90.1) surface antigen, particularly for targeting and eliminating specific T cell populations in experimental models. These are the primary in vivo applications:
In summary, the most common in vivo application of clone 19E12 in mice is antibody-mediated depletion of Thy1.1+ cell populations, particularly for manipulating or studying T cells in immunological, transplantation, and tumor models. Commonly used antibodies or proteins paired with 19E12 (anti-mouse Thy1.1/CD90.1) in the literature include those targeting CD45 (pan-leukocyte marker), CD3 (T cell marker), and CD4/CD8 (helper/cytotoxic T cell markers). These are used in multiparametric flow cytometry and depletion studies to identify and characterize lymphocyte subsets and other immune cell populations in mouse models. Additional context and usage details include:
Summary table of common pairings:
Secondary antibodies (e.g., anti-rat IgG, anti-mouse IgG) conjugated to various fluorochromes are also routinely used for multicolor detection in flow cytometry and immunohistochemistry setups. In summary, CD45, CD3, CD4, and CD8 antibodies are most commonly used together with 19E12 for immunophenotyping and functional studies of mouse immune cells. Additional markers may be added depending on the specific design and objectives of the experiment. Key findings from scientific literature citing clone 19E12 center on its specificity for mouse Thy1.1 (CD90.1), its utility in precise immunological targeting, and its roles in cell depletion and cancer research.
No substantial findings link "clone 19E12" to resistance genes or systemic reviews outside of immunology and tumor biology, suggesting its principal relevance is as an experimental reagent in mouse model research and antibody engineering. Dosing regimens for clone 19E12 (anti-mouse Thy1.1/CD90.1) are tailored to experimental objectives and can vary across mouse models according to strain, target cell population, and intended outcome such as T cell depletion, tumor targeting, or immunomodulation. In published usage, clone 19E12 was originally generated for specificity to the Thy1.1 antigen in mouse strains like 129 and AKR—models where Thy1.1 is naturally expressed. In these models, 19E12 has been deployed to:
Key factors affecting dose and schedule:
Examples from literature:
General principles echoed for in vivo antibody dosing in murine models:
In sum, clone 19E12 dosing is adjusted for the mouse strain’s Thy1.1 expression, the immunological goal (depletion vs targeting), and the specific experimental design; regimens may range from single to multiple intraperitoneal injections, often at 100–250 μg per dose, generally given every few days, but are best optimized based on population, immune status, and intended outcome. References & Citations1 Bradley JE, Ramirez G, Hagood JS. Biofactors. 35(3):258-265. 2009. 2 Haeryfar SM, Hoskin DW. J Immunol. 173(6):3581-3588. 2004. 3 Bernstein ID, Tam MR, Nowinski RC. Science. 207(4426):68-71. 1980. 4 Badger CC, Bernstein ID. J Exp Med. 157(3):828-842. 1983. 5 Sauvage CA, Mendelsohn JC, Lesley JF, et al. Cancer Res. 47(3):747-753. 1987. 6 Staerz UD, Bevan MJ. Proc Natl Acad Sci U S A. 83(5):1453-1457. 1986. 7 Moro M, Pelagi M, Fulci G, et al. Cancer Res. 57(10):1922-1928. 1997. 8 Scott-Browne JP, Shafiani S, Tucker-Heard G, et al. J Exp Med. 204(9):2159-2169. 2007. 9 Badell IR, Kitchens WH, Wagener ME, et al. Am J Transplant. 15(12):3081-3094. 2015. 10 Kim J, Jeong Ryu S, Oh K, et al. Nat Commun. 6:7994. 2015. 11 Liu B, Lee JB, Chen CY, et al. J Immunol. 194(8):3583-3593. 2015. 12 Campisi L, Barbet G, Ding Y, et al. Nat Immunol. 17(9):1084-1092. 2016. 13 Mestas J, Hughes CC. J Immunol. 172(5):2731-2378. 2004. Technical ProtocolsCertificate of Analysis |
Formats Available
